Investing.com -- RegenLab USA, Inc., a Swiss-founded regenerative medicine developer specializing in point-of-care cell processing devices, has filed a Form S-1 registration statement with the SEC to raise capital via an initial public offering. The Jersey City, New Jersey-based company plans to list on the Nasdaq Stock Market under the ticker RGNA, with StoneX Financial Inc. acting as sole book-running manager.
Founded by Chairman and CEO Antonino Turzi, who holds 98.64% of voting power, RegenLab operates integrated R&D and manufacturing hubs across New Jersey, France, and Switzerland.
Financial results highlight accelerating top-line momentum, with net product sales rising 21% year-over-year to $29.32 million for the six months ended June 30, 2026. The revenue expansion drove a return to profitability, yielding operating income of $2.10 million and net income of $71,000, up from an operating loss of $0.77 million and a net loss of $32,000 in the prior-year period. Full-year 2025 revenue reached $49.17 million, though increased R&D spending led to a full-year net loss of $1.24 million.
The company's revenue remains heavily anchored in its core biological platforms, which generated...